Significant underutilization of angiotensin receptor neprolysin inhibitor (ARNI) and other evidence-based heart failure (HF) therapies in an outpatient clinic setting
Reduction of NT-proBNP in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction in short-term treatment with empagliflozin on top of existing therapy